Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 25, 2010, Pages 11313-11318

  Cho, Yoonsang ^a   Crichlow, Gregg V ^a   Vermeire, Jon J ^a   Leng, Lin ^a   Du, Xin ^a   Hodsdon, Michael E ^a   Bucala, Richard ^a   Cappello, Michael ^a   Gross, Matt ^b   Gaeta, Federico ^b   Johnson, Kirk ^b,c   Lolis, Elias J ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Avigen Inc   (United States)

^c MediciNova Inc   (United States)

^d YALE CANCER CENTER   (United States)

Author keywords

Cross reactivity; Cytokine; Drug repositioning; Inflammation

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; AC 1013; ANTIBODY; AV 1013; CHEMOKINE RECEPTOR CXCR2; IBUDILAST; MACROPHAGE MIGRATION INHIBITION FACTOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG; 4 HYDROXYPHENYLPYRUVIC ACID; 4-HYDROXYPHENYLPYRUVIC ACID; ANTITHROMBOCYTIC AGENT; CYTOKINE; ISOMERASE; PHENYLPYRUVATE TAUTOMERASE; PHENYLPYRUVIC ACID; PYRIDINE DERIVATIVE;

ALLOSTERISM; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; CATALYSIS; CHEMOTAXIS; COMPLEX FORMATION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; NUCLEAR MAGNETIC RESONANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY; CHEMISTRY; INFLAMMATION; KINETICS; METABOLISM; METHODOLOGY; PROTEIN BINDING; SPECTROFLUOROMETRY;

ALLOSTERIC SITE; BINDING SITES; CATALYSIS; CHEMOTAXIS; CRYSTALLOGRAPHY, X-RAY; CYTOKINES; HUMANS; INFLAMMATION; INTRAMOLECULAR OXIDOREDUCTASES; KINETICS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; PHENYLPYRUVIC ACIDS; PLATELET AGGREGATION INHIBITORS; PROTEIN BINDING; PYRIDINES; SPECTROMETRY, FLUORESCENCE;

EID: 77954926921     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1002716107     Document Type: Article

References (46)

1. Nakahara T, et al. (2002) Relaxation and potentiation of cGMP-mediated response by ibudilast in bovine tracheal smooth muscle. N-S Arch Pharmakol 366:262-269.
2. Kishi Y, et al. (2000) Ibudilast modulates platelet-endothelium interaction mainly through cyclic gmp-dependent mechanism. J Cardiovasc Pharma 36:65-70.
3. Milligan ED, Watkins LR (2009) Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 10:23-36.
4. Hutchinson MR, et al. (2009) Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 23:240-250.
5. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW (2007) Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Inv Drug 16:935-950.
6. Ledeboer A, et al. (2006) The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol 2:279-291.
7. Bloom BR, Bennett B (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80-82.
8. David JR (1966) Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56:72-77.
9. Wang F, et al. (2010) Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats. Pain 148:275-283.
10. Nishibori M, et al. (1996) Presence of macrophage migration inhibitory factor (MIF) in ependyma, astrocytes and neurons in the bovine brain. Neurosci Lett 213:193-196.
11. Lolis E (2001) Glucocorticoid counter regulation: Macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol 1:662-668.
12. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 3:791-800. (Pubitemid 37328657)
13. Shi X, et al. (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25:595-606.
14. Weber C, et al. (2008) Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment. Proc Natl Acad Sci USA 105:16278-16283.
15. Bernhagen J, et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13:587-596.
16. Lolis E, Bucala R (2003) Macrophage migration inhibitory factor. Expert Opin Ther Tar 7:153-164.
17. Sun HW, et al. (1996) The subunit structure of human macrophage migration inhibitory factor: Evidence for a trimer. Protein Eng 9:631-635.
18. Sun HW, Bernhagen J, Bucala R, Lolis E (1996) Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. Proc Natl Acad Sci USA 93:5191-5196.
19. Swope MD, Lolis E (1999) Macrophage migration inhibitory factor: Cytokine, hormone, or enzyme. Rev Physiol Biochem Pharmacol 139:1-32.
20. Rosengren E, et al. (1997) The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett 417:85-88.
21. Rosengren E, et al. (1996) The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 2:143-149.
22. Swope M, Sun HW, Blake PR, Lolis E (1998) Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor. EMBO J 17:3534-3541.
23. Lubetsky JB, et al. (2002) The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem 277:24976-24982.
24. Al-Abed Y, et al. (2005) ISO-1 binding to the tautomerase active site of mif inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 280:36541-36544.
25. Crichlow GV, et al. (2007) Alternative chemical modifications reverse the binding orientation of a pharmacophore scaffold in the active site of macrophage migration inhibitory factor. J Biol Chem 282:23089-23095.
26. Rolan P, et al. (2008) Ibudilast in healthy volunteers: Safety, tolerability and pharmacokinetics with single and multiple doses. Brit J Clin Pharmaco 66:792-801.
27. Mizuno T, et al. (2004) Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology 46:404-411.
28. Crichlow GV, Lubetsky JB, Leng L, Bucala R, Lolis EJ (2009) Structural and kinetic analyses of macrophage migration inhibitory factor active site interactions. Biochemistry 48:132-139.
29. Deutsch JC (1997) Determination of p-hydroxyphenylpyruvate, p-hydroxyphenyllactate and tyrosine in normal human plasma by gas chromatography-mass spectrometry isotope-dilution assay. J Chromatogr B 690:1-6.
30. Kleemann R, et al. (2000) Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408:211-216.
31. Jung H, Kim T, Chae HZ, Kim KT, Ha H (2001) Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction. J Biol Chem 276:15504-15510.
32. Wadgaonkar R, et al. (2005) Intracellular interaction of myosin light chain kinase with macrophage migration inhibition factor (MIF) in endothelium. J Cell Biochem 95:849-858.
33. Leng L, et al. (2003) MIF signal transduction initiated by binding to CD74. J Exp Med 197:1467-1476.
34. Li Y, Lu C, Xing G, Zhu Y, He F (2004) Macrophage migration inhibitory factor directly interacts with hepatopoietin and regulates the proliferation of hepatoma cell. Exp Cell Res 300:379-387.
35. Jung H, Seong H-A, Ha H (2008) Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J Biol Chem 283:20383-20396.
36. Jung H, Seong H-A, Ha H (2008) Direct interaction between Nm23-H1 and macrophage amigration inhibitory factor (MIF) ss critical for alleviation of MIF-mediated suppression of p53 activity. J Biol Chem 283:32669-32679.
37. Liu L, et al. (2008) Macrophage migration inhibitory factor (MIF) interacts with Bim and inhibits Bim-mediated apoptosis. Mol Cells 26:193-199.
38. Son A, et al. (2009) Direct association of thioredoxin-1 (TRX) with macrophage migration inhibitory factor (MIF): Regulatory role of TRX on MIF internalization and signaling. Antioxid Redox Sign 11:2595-2605.
39. Merk M, et al. (2009) The golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. J Immunol 182:6896-6906.
40. Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL (2010) Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation. Cancer Lett 290:49-57.
41. Lee GM, Craik CS (2009) Trapping moving targets with small molecules. Science 324:213-215.
42. Mizue Y, et al. (2005) Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA 102:14410-14415.
43. Yamaguchi E, et al. (2000) Macrophage migration inhibitory factor (MIF) in bronchial asthma. Clin Exp Allergy 30:1244-1249.
44. Cho Y, et al. (2007) Structural and functional characterization of a secreted hookworm Macrophage Migration Inhibitory Factor (MIF) that interacts with the human MIF receptor CD74. J Biol Chem 282:23447-23456.
45. Samworth CM, Degli Esposti M, Lenaz G (1988) Quenching of the intrinsic tryptophan fluorescence of mitochondrial ubiquinol-cytochrome-c reductase by the binding of ubiquinone. Eur J Biochem 171:81-86.
46. Muhlhahn P, et al. (1996) NMR characterization of structure, backbone dynamics, and glutathione binding of the human macrophage migration inhibitory factor (MIF). Protein Sci 5:2095-2103.